Frequency of infective pulmonary exacerbations: number of exacerbations per patient year · adults and children with cystic fibrosis and a positive microbiological isolate of P aeruginosa from a respiratory tract specimen
1 finding from 1 review
Frequency of infective pulmonary exacerbations: number of exacerbations per patient year · adults and children with cystic fibrosis and a positive microbiological isolate of P aeruginosa from a respiratory tract specimen
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Frequency of infective pulmonary exacerbations: number of exacerbations per patient year · adults and children with cystic fibrosis and a positive microbiological isolate of P aeruginosa from a respiratory tract specimen
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Frequency of infective pulmonary exacerbations: number of exacerbations per patient year · adults and children with cystic fibrosis and a positive microbiological isolate of P aeruginosa from a respiratory tract specimen
It is very uncertain whether inhaled tobramycin (TNS) (28 days) changes frequency of infective pulmonary exacerbations: number of… compared with TNS (56 days) (very low certainty).
1 finding from 1 review
Frequency of infective pulmonary exacerbations: number of exacerbations per patient year · adults and children with cystic fibrosis and a positive microbiological isolate of P aeruginosa from a respiratory tract specimen
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Frequency of infective pulmonary exacerbations: number of participants experiencing an exacerbation · children with cystic fibrosis and a new culture positive for P aeruginosa
Inhaled tobramycin (TNS) plus oral azithromycin showed no clear difference in frequency of infective pulmonary exacerbations: number of… compared with TNS plus oral placebo (moderate certainty).
1 finding from 1 review
Pulmonary exacerbations · adults (aged 16 years and over) with CF
Digital technology (web‐based platform CFHealthHub) probably leads to lower number of pulmonary exacerbations compared with usual care (moderate certainty).
1 finding from 1 review
Pulmonary exacerbations · children aged 5 to 16 years
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Pulmonary exacerbations · adults and children with cystic fibrosis and a positive microbiological isolate of P aeruginosa from a respiratory tract specimen
Summary of findings: colistimethate dry powder for inhalation… showed no clear difference in pulmonary exacerbations: number of pulmonary exacerbations compared with tobramycin (moderate certainty).
1 finding from 1 review
Exacerbations (number of people experiencing ≥ 1 exacerbations) · adults and children with cystic fibrosis and a positive microbiological isolate of P aeruginosa from a respiratory tract specimen
Summary of findings: tobramycin for inhalation powder showed no clear difference in pulmonary exacerbations: number of participants experiencing… compared with tobramycin (moderate certainty).
1 finding from 1 review
Pulmonary exacerbations: number of hospitalisations due to respiratory exacerbations · adults and children aged over 12 with CF and P aeruginosa
Summary of findings: levofloxacin for inhalation solution leads to lower pulmonary exacerbations: number of hospitalisations due to… compared with tobramycin (high certainty).
1 finding from 1 review